Impact of SARS-CoV-2 envelope protein mutations on the pathogenicity of Omicron XBB
Open Access
- 28 July 2023
- journal article
- letter
- Published by Springer Nature in Cell Discovery
- Vol. 9 (1) , 1-4
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (31700732, 81773707)
This publication has 14 references indexed in Scilit:
- Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariantsCell, 2022
- Omicron Subvariants: Clinical, Laboratory, and Cell Culture CharacterizationClinical Infectious Diseases, 2022
- Alpha to Omicron: Disease Severity and Clinical Outcomes of Major SARS-CoV-2 VariantsThe Journal of Infectious Diseases, 2022
- Why is the SARS-CoV-2 Omicron variant milder?The Innovation, 2022
- Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variantNature, 2022
- SARS-CoV-2 envelope protein causes acute respiratory distress syndrome (ARDS)-like pathological damages and constitutes an antiviral targetCell Research, 2021
- TLR2 senses the SARS-CoV-2 envelope protein to produce inflammatory cytokinesNature Immunology, 2021
- Characteristics of SARS-CoV-2 variants of concern B.1.1.7, B.1.351 or P.1: data from seven EU/EEA countries, weeks 38/2020 to 10/2021Eurosurveillance, 2021
- Coronaviruses: Innate Immunity, Inflammasome Activation, Inflammatory Cell Death, and CytokinesTrends in Immunology, 2020
- The phylogenomics of evolving virus virulenceNature Reviews Genetics, 2018